Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside

Research output: Contribution to journalReview article

Abstract

The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative breast cancer (BC) expressing PD-L1. Nonetheless, immune checkpoint inhibitors (ICIs) are still challenged by the resistance and immune-related adverse effects evident in a considerable subset of treated patients without conclusive comprehension of the underlying molecular basis, biomarkers and tolerable therapeutic regimens capable of unleashing the anti-tumour immune responses. Stepping back to preclinical models is thus inevitable to address these inquiries. Herein, we comprehensively review diverse preclinical models of BC exploited in investigating ICIs underscoring their pros and cons as well as the learnt and awaited lessons to allow full exploitation of ICIs in BC therapy.

Original languageEnglish
Pages (from-to)22-41
Number of pages20
JournalEuropean Journal of Cancer
Volume122
DOIs
Publication statusPublished - Nov 2019

Keywords

  • Breast cancer
  • CTLA-4
  • Immune checkpoint inhibitor
  • PD-1
  • PD-L1
  • Preclinical model

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside'. Together they form a unique fingerprint.

  • Cite this